If folks remember, GNBT has already gone through months of much more stringent testing that the other vaccines with "Emergency" approvals have not even come close to. That is a documented fact. Also, GNBT has been taking guidance from the FDA along the way. I thought I read somewhere on this board, due to the more stringent testing, that GNBT will not be required to have a high number of samples for the trials & that the trials may be run concurrently. Anyways, I may be wrong, but maybe our board expert, doc, can address that for the board. Regardless, to pull "pie-out-of-sky numbers" such as Feb 2022, would not be reasonable considering where GNBT is at currently IMHO. Hey, we may be later to the approval process than a few vaccines, but our vaccine, the "complete vaccine" has gone through much more stringent testing and is a potential game changer! One other thing to think about, most of our contracts, if not all our contracts, are with foreign country's such as China, Malaysia, and others. Maybe they saw the vast potential here long long ago. Also, as we all know, many foreign country's are behind the power curve when compared to the USA. Folks would love GNBT's product IMHO. Only time will tell. We also have our subsidiary, NGIO, up-listing to the NASDAQ coming to fruition hopefully soon. Much to look forward to here. GLTA!
AI
